FIELD: clinical hematology. SUBSTANCE: composition is characterized by specific activity, purity above 95%, and, when applied on humans, by considerably reduced side effects usually associated with alpha-interferon compositions. Composition can be used therapeutically when treating cancer diseases, immune system diseases, and/or viral etiology. EFFECT: extended choice of antitumor and immuno-modulating drugs. 9 cl, 9 dwg, 19 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES RAISED AGAINST α-INTERFERON | 2002 |
|
RU2314317C2 |
| IMMUNITY-INDUCING AGENT | 2012 |
|
RU2634862C2 |
| PROTEIN SHOWING INTERFERON-LIKE ANTIVIRAL AND ANTIPROLIFERATIVE BIOLOGICAL ACTIVITIES (VERSIONS), PROTEIN STRUCTURE, CODING POLYNUCLEOTIDE (VERSIONS), EXPRESSION VECTOR, HOST CELL, COMPOSITION AND USE OF PROTEIN AS ANTIVIRAL, ANTIPROLIFERATIVE, ANTICANCER OR IMMUNOMODULATORY AGENT AND METHOD OF TREATING CONDITION SENSITIVE TO INTERFERON-THERAPY, CANCER OR VIRAL DISEASE | 2007 |
|
RU2469091C2 |
| INTERFERON-LIKE PROTEIN ZCYTO21 | 2001 |
|
RU2292394C2 |
| NOVEL SOLUBLE POLYPEPTIDES CD83, COMPOSITIONS AND METHODS OF THEIR APPLICATION | 2009 |
|
RU2535340C2 |
| PEGYLATED RECOMBINANT CONSENSUS INTERFERON VERSION CONJUGATE AND PREPARATION METHOD AND USE THEREOF | 2011 |
|
RU2575796C9 |
| POLYPEPTIDE WITH ANTIVIRAL ACTIVITY, ITS PRODUCTION AND USE | 2004 |
|
RU2372356C2 |
| HOMOGENOUS PREPARATIONS OF IL-28 AND IL-29 | 2004 |
|
RU2518324C2 |
| IMMUNITY-INDUCING MEANS | 2012 |
|
RU2614386C2 |
| HUMANISED ANTIBODIES AGAINST HUMAN ALPHA INTERFERON | 2009 |
|
RU2532832C2 |
